Actuate Therapeutics, Inc. ACTU
We take great care to ensure that the data presented and summarized in this overview for ACTUATE THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ACTU
Top Purchases
Top Sells
About ACTU
Insider Transactions at ACTU
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 27
2025
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Indirect |
71,428
+26.67%
|
$499,996
$7.0 P/Share
|
|
Jun 27
2025
|
Leslie W. Kreis Director |
BUY
Open market or private purchase
|
Indirect |
71,428
+26.67%
|
$499,996
$7.0 P/Share
|
|
Jun 27
2025
|
Bios Equity Cof, LP Director |
BUY
Open market or private purchase
|
Indirect |
71,428
+26.67%
|
$499,996
$7.0 P/Share
|
|
Aug 14
2024
|
Todd S Thomson Director |
SELL
Open market or private sale
|
Indirect |
18,750
-1.56%
|
$150,000
$8.0 P/Share
|
|
Aug 14
2024
|
Todd S Thomson Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
28,464
+2.31%
|
$142,320
$5.27 P/Share
|
|
Aug 14
2024
|
Todd S Thomson Director |
BUY
Conversion of derivative security
|
Indirect |
2,577,312
+30.43%
|
-
|
|
Aug 14
2024
|
Bios Equity Cof, LP Director |
SELL
Open market or private sale
|
Indirect |
24,999
-1.74%
|
$224,991
$9.0 P/Share
|
|
Aug 14
2024
|
Bios Equity Cof, LP Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
37,951
+2.57%
|
$189,755
$5.27 P/Share
|
|
Aug 14
2024
|
Bios Equity Cof, LP Director |
BUY
Conversion of derivative security
|
Indirect |
9,380,699
+37.41%
|
-
|
|
Aug 14
2024
|
Bios Equity Cof, LP Director |
BUY
Open market or private purchase
|
Indirect |
500,000
+36.47%
|
$4,000,000
$8.0 P/Share
|
|
Aug 14
2024
|
Aaron G.L. Fletcher Director |
SELL
Open market or private sale
|
Indirect |
24,999
-1.74%
|
$224,991
$9.0 P/Share
|
|
Aug 14
2024
|
Aaron G.L. Fletcher Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
37,951
+2.57%
|
$189,755
$5.27 P/Share
|
|
Aug 14
2024
|
Aaron G.L. Fletcher Director |
BUY
Conversion of derivative security
|
Indirect |
9,380,699
+37.41%
|
-
|
|
Aug 14
2024
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Indirect |
500,000
+36.47%
|
$4,000,000
$8.0 P/Share
|
|
Aug 14
2024
|
Leslie W. Kreis Director |
SELL
Open market or private sale
|
Indirect |
24,999
-1.74%
|
$224,991
$9.0 P/Share
|
|
Aug 14
2024
|
Leslie W. Kreis Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
37,951
+2.57%
|
$189,755
$5.27 P/Share
|
|
Aug 14
2024
|
Leslie W. Kreis Director |
BUY
Conversion of derivative security
|
Indirect |
9,380,699
+37.41%
|
-
|
|
Aug 14
2024
|
Leslie W. Kreis Director |
BUY
Open market or private purchase
|
Indirect |
500,000
+36.47%
|
$4,000,000
$8.0 P/Share
|
Last 12 Months Summary
Buy / Acquisition
214K
Shares
From
3
Insiders
| Open market or private purchase | 214K shares |
|---|
Sell / Disposition
0
Shares
From
0
Insiders